Literature DB >> 25146913

Ovarian hyperstimulation syndrome and thrombotic events.

Yechiel S Mor1, Joseph G Schenker.   

Abstract

Ovarian hyperstimulation syndrome (OHSS) is one of the most important complications of ovarian stimulation with severe morbidity and is still a threat to every patient undergoing ovulation induction. This manuscript reviews the current evidence regarding the relationship between OHSS and thromboembolism in infertile patients undergoing ovarian stimulation published in the world literature. The PubMed Database was searched for publications on reported cases of OHSS and thromboembolic phenomenon published between 1965 and 2013. One hundred and forty cases of OHSS and thromboembolic phenomena were retrieved. The vascular accident had already occurred in the first cycle of treatment among 119 women (85%), at early stage of OHSS in 43% and late stage in 57% of cases. Venous thrombotic events were recorded mostly in unusual sites, jugular, and subclavian veins, with 69 and 38 thrombotic events, respectively. Coagulation status was found at 86 of the 140 cases (61%). Fifty-three of the pregnant patients (68%) delivered singleton births and 47% had preterm deliveries, and termination of pregnancy was indicated in 11 cases (14%). The most serious complication associated with OHSS is thrombotic phenomena as shown in the present review of 140 cases, world data, on both arterial and venous side. Thromboprophylaxis should be initiated in patients with thrombophilia and who develop moderate-to-severe OHSS.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Anticoagulant therapy; assisted reproductive technology; ovarian hyperstimulation syndrome; thrombophilia; thrombosis

Mesh:

Year:  2014        PMID: 25146913     DOI: 10.1111/aji.12310

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  7 in total

1.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

Review 2.  In vitro Fertilization Procedures with Embryo Transfer and Their Association with Thrombophilia, Thrombosis and Early Antithrombotic Treatments.

Authors:  Pierpaolo Di Micco; Vincenzo Russo; Daniela Mastroiacovo; Marijan Bosevski; Corrado Lodigiani
Journal:  J Blood Med       Date:  2020-06-11

Review 3.  Thrombophilia and assisted reproduction technology-any detrimental impact or unnecessary overuse?

Authors:  Baris Ata; Bulent Urman
Journal:  J Assist Reprod Genet       Date:  2016-07-16       Impact factor: 3.412

4.  Common carotid artery thrombosis and malignant middle cerebral artery infarction following ovarian hyperstimulation syndrome: A case report.

Authors:  Yan-Ting Xu; Qian-Qian Yin; Zhao-Rong Guo
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

5.  Ovarian hyperstimulation syndrome as a rare cause of acute bilateral limb and renal ischemia.

Authors:  Anita Quintas; Maria Emilia Ferreira; Frederico Bastos Gonçalves; José Aragão de Morais; Joao Albuquerque E Castro; Luís Mota Capitao
Journal:  J Vasc Surg Cases Innov Tech       Date:  2017-06-01

6.  The Effects of Administrated Sildenafil Citrate on Uterine Luminal Epithelium Height Associated with Ovarian Angiogenesis: An Experimental Animal Study.

Authors:  Mohammad Hosein Golkar; Mohammad Javad Saeedi Borujeni; Bahman Rashidi
Journal:  Adv Biomed Res       Date:  2017-12-26

7.  The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.

Authors:  Erica Velthuis; Julie Hubbard; Salvatore Longobardi; Thomas D'Hooghe
Journal:  Adv Ther       Date:  2020-10-15       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.